Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis.

"Transparency declarations: J.J.M. has received funds for symposia or lectures organized by Gilead Sciences. He attended advisory board meetings of Gilead Sciences and Astra Zeneca. All other authors: none to declare.: Author contributionsN.S., J.J.M. and S.W. conceptualized the research question and study protocol. Risk of bias assessment for included RCTs was done by S.W., N.S. and N.K. Data extraction, statistical analysis and visualization was performed by S.W., N.K. and N.S. J.J.M., S.W., H.G., N.K., M.S. and N.S. were involved in critical discussion of the results from a clinical, virological and methodological point of view. J.J.M., S.W. and N.S. wrote the original manuscript. All authors were involved in critical revision for important intellectual content and approved the final version of the manuscript."

"Funding This research was carried out as part of our routine work."

"The protocol for this systematic review was registered on the International prospective register of systematic reviews (PROSPERO, identifier CRD42022306644) and made publicly available on 25 January 2022."